Title
Preventing and treating olanzapine-induced obesity with betahistine: a chronic animal model study
Document Type
Conference Paper
RIS ID
72350
Abstract
Objective : Olanzapine, an atypical antipsychotic drug, is widely prescribed to treat schizophrenia, but induces serious weight gain/ obesity side-effects. Antipsychotic drugs antagonistic affinity for histamine H1 receptors is the main indicator of weight gain side-effects. This study aimed to investigate whether chronic treatment with betahistine (H1 receptor agonist/H3 receptor antagonist) could prevent/ treat olanzapine-induced weight gain at different stages of treatment.
Methods : Female Sprague-Dawley rats were administered under 5 conditions (n=12) : (1) Rats were treated with vehicle (control) during whole experimental period ; (2) ‘‘Obesity treatment group’’ : 5 weeks olanzapine treatment (1 mg/kg, t.i.d.), followed by 6 weeks coadministration of olanzapine with betahistine (9.6 mg/kg, t.i.d.) ; (3) ‘‘Obesity prevention group’’ : 3.5 weeks olanzapine treatment, followed by 2.5 weeks withdrawed, then co-administration of olanzapine and betahistine (4.8 mg/kg, t.i.d.) was introduced ; (4) Sole olanzapine treatment following the same time course as Group 3 ; (5) Rats were treated solely with betahistine (4.8 mg/kg, t.i.d.) during weeks 7–11.
Results : Compared to controls, olanzapine treatment increased body weight (p
Conclusion: This study revealed that chronic co-treatment of olanzapine and betahistine is effective at reducing olanzapineinduced obesity side-effects. These results provide support for further clinical trials to improve of olanzapine-induced obesity side-effects using betahistine co-treatment.
This record is in the process of being updated. Please contact us for more information.
Publication Details
Lian, J., Huang, X., Pai, N. B. and Deng, C. (2012). Preventing and treating olanzapine-induced obesity with betahistine: a chronic animal model study. The International Journal of Neuropsychopharmacology,: Abstracts from the 28th CINP World Congress of Neuropsychopharmacology (pp. 56-56). United Kingdom: Cambridge Journals.